The present study determined the feasibility of detecting and quantifying the expression level of lncRNAs in the plasma of patients with BC and assessed 3 lncRNAs (ANRIL, HIF1A-AS2, and UCA1) as novel noninvasive diagnostic biomarkers for differentiating between TNBC and non-TNBC (NTNBC) in the clinical setting. This evidence concerns the gene CDKN2B-AS1 and breast cancer.